Johnson & Johnson Proposes $5.5 Billion Settlement to Resolve Talc Lawsuits

Johnson & Johnson (J&J) has offered up to $5.5 billion to settle tens of thousands of lawsuits in the United States alleging that its talcum-based baby powder and other products caused ovarian cancer. The proposed settlement covers approximately 69,000 cases in federal and state courts, accounting for 99.75% of outstanding talc-related claims in the country.

To be finalized, the agreement must be accepted by legal firms representing 95% of the ovarian cancer claimants or approved by a federal judge in New Jersey. J&J's vice president of litigation, Erik Haas, described the allegations as "meritless," stating that while the company is confident it would have ultimately prevailed in court, the resolution allows J&J to put the matter behind it and focus on its medical mission.

J&J has long denied that its talc products cause cancer or contain asbestos. The company stopped selling talc-based baby powder in the U.S. in 2020 and worldwide in 2023, transitioning to a cornstarch-based portfolio. Litigation resumed in March 2025 following several failed attempts by J&J to resolve the claims through bankruptcy proceedings involving a shell company. Additionally, a recent federal court victory for J&J saw a judge question the ability of individual plaintiffs to prove that talc was the direct cause of their cancer.

The agreement applies only to existing claims and does not address future lawsuits. It also excludes a separate legal action in the United Kingdom involving more than 7,000 potential claimants, which alleges J&J knew its talc could cause ovarian cancer and mesothelioma.

Outlets with center-left leans framed the event by highlighting health risks, noting that the World Health Organization classified talc as "probably carcinogenic to humans." In contrast, outlets with center-right leans emphasized J&J's legal defenses, including its recent court victories and previous attempts to resolve litigation via bankruptcy.